thank you again. you´re a wealth of information. The abstract was a tad over my IQ. Yet, i will continue to study it. have a great afternoon.
Investors will have their first view into the
durability of this effect with the presentation of 18-month data expected at the
European Society for Paediatric Endocrinology (ESPE) in the first week of
my bad. I read that OPK adults trial is monthly thus my conclusion they could use it of label for kids. is OPK in front of VSAR on adult trials ?
plus sales teams don't get ramped up usually until 1 year out. look at ACDA . they are now just building a sales team
why would Pfizer be a buyer if they have a deal in same space with OPK? apologize if its dumb Q. thanks tony for the help.
It seems from my top line DD ( don't want to miss the bottom here ? ) that OPK could get FDA approval first on adult drug thus Docs could use off label for kids thereby eroding potential market opp for VSAR. is this a concern ? furthermore, will VSAR miss the adult market OPP ? lastly is there anything proprietary / patentable here is it a first to market race , land grab situation. thanks gentlemen. want to get just want to cover my top line Q. blessing from los cabos. beers on me if you make it down here or a free membership for life my site trackingtheisiders.com. if you want it... RG
sorry did not mean to offend was just trying expidite my learning curve to take advantage of the price per share as I think it will move UP fast once we see insiders adding or at least the BB. I have been following them for years via SGEN AND ACAD. this is new space for me. once again, sorry to annoy not my objective. god bless brother.
thanks tony, I read the following in a old thread. the gentlemen seemed very knowledgeable. (over billion in sales with less than 30% market penetration )
your model is what 400mm per yr. is that in the US alone ? do believe that's how he got to 1bb mark ?
thank you again. I read the below regarding market size
VSAR drug could be a blockbuster (over billion in sales with less than 30% market penetration in the US. does this seem accurate ?
thank you much Rosettwest. last Q if that's ok , does the daily show results within 6 months ? do find it odd that VSAR does not ?
last Q , how big is the opportunity if they get approval ? in US and EEU
why is the monthly better then a daily regime of current drugs , outside of the obvious / less swallowing.
thanks gentlemen. I want to pick up shares here. TY